Recurrence-free survival is a valid surrogate endpoint for overall survival in surgically resectable advanced oesophageal squamous cell carcinoma (oscc) patients receiving neoadjuvant chemotherapy. A strong correlation (kendall’s τ 0.797) was found between the two endpoints, particularly in patients with a more favorable response to neoadjuvant treatment. This suggests that recurrence-free survival can be used as a reliable predictor of overall survival outcomes in oscc patients.
Journal Article by Okui J, Nagashima K (…) Kitagawa Y et 17 al. in Br J Surg
© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd.